Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG).

Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Asociación para Evitar la Ceguera en México
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization

• Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment

• Completely studies

Exclusion Criteria:

Complications

• Tractional Detachment

• Endophthalmitis